Vicarious Surgical 8-K: Officer/Director Changes, Comp Arrangements

TL;DR

**Vicarious Surgical filed an 8-K about executive changes and compensation on Jan 25.**

AI Summary

Vicarious Surgical Inc. filed an 8-K on January 29, 2024, reporting events that occurred on January 25, 2024. The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'. This matters to investors because changes in leadership or executive compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting stock valuation.

Why It Matters

Changes in executive leadership and compensation can significantly influence a company's direction and investor confidence, directly affecting stock performance.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty, but the specific details of the changes are not provided in this summary, making the risk level moderate.

Analyst Insight

Investors should look for subsequent filings or press releases from Vicarious Surgical Inc. that provide specific details about the executive changes and compensatory arrangements to assess their potential impact on the company's future.

Key Players & Entities

• Vicarious Surgical Inc. (company) — the registrant filing the 8-K
• January 25, 2024 (date) — date of the earliest event reported
• January 29, 2024 (date) — date the 8-K was filed
• 001-39384 (other) — Commission File Number
• 78 Fourth Avenue Waltham, Massachusetts 02451 (other) — business address of Vicarious Surgical Inc.
• (617) 868-1700 (other) — business phone number of Vicarious Surgical Inc.

FAQ

Key Financial Figures

• $0.0001 — tered Class A common stock, par value $0.0001 per share RBOT The New York Stock E
• $11.50 — mon stock, each at an exercise price of $11.50 per share RBOT WS The New York Stoc
• $500,000 — tter, Mr. Clark's annual base salary is $500,000. Mr. Clark is eligible to receive an an

Filing Documents

• ea192327-8k_vicarious.htm (8-K) — 30KB
• ea192327ex99-1_vicarious.htm (EX-99.1) — 12KB
• 0001213900-24-007204.txt ( ) — 262KB
• rbot-20240125.xsd (EX-101.SCH) — 4KB
• rbot-20240125_def.xml (EX-101.DEF) — 26KB
• rbot-20240125_lab.xml (EX-101.LAB) — 36KB
• rbot-20240125_pre.xml (EX-101.PRE) — 25KB
• ea192327-8k_vicarious_htm.xml (XML) — 6KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 29, 2024, Vicarious Surgical Inc. (the "Company") announced the appointment of Randy Clark as the President of the Company, effective as of the same day (the "Appointment Date"). In connection with the appointment of Mr. Clark, Adam Sachs stepped down from his role as President. Mr. Sachs will continue to serve as the Chief Executive Officer of the Company. Mr. Clark, age 48, served as the Global President of the Health Solutions business at Flex Ltd. (Nasdaq: FLEX), a global supply chain, manufacturing, and design solutions provider, since January 2022. Prior to joining Flex Ltd., Mr. Clark spent 15 years at Olympus Corporation of the Americas, a medical technology and equipment manufacturing company, from 2005 until January 2022, where he held various roles with increasing responsibilities, ultimately serving as President and member of their board of directors. Mr. Clark earned a Bachelor of Science in Business Administration from Drake University, a Master of Business Administration degree from Colorado State University, and completed the Advanced Management program at Harvard Business School. The Company has entered into an offer letter of employment with Mr. Clark, effective as of the Appointment Date (the "Offer Letter"). Pursuant to the terms of the Offer Letter, Mr. Clark's annual base salary is $500,000. Mr. Clark is eligible to receive an annual discretionary bonus with a target of 50% of his base salary. The Offer Letter further provides that Mr. Clark is eligible to receive a stock option for the purchase of 1,000,000 shares of Class A common stock of the Company, subject to approval by the Compensation Committee of the Board of Directors. Mr. Clark entered into an indemnification agreement in the form the Company has entered into with its other executive officers, which form is file

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VICARIOUS SURGICAL INC. By: /s/ Adam Sachs Name: Adam Sachs Title: Chief Executive Officer Date: January 29, 2024 2

View Full Filing

View this 8-K filing on SEC EDGAR